Subscribe To

Price Alert Latest News Economic Calendar News

BPTS / Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 9, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announced that it presents the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at the European Respiratory Society 2023 21st Lung Science Conference taking place in Estoril, Portugal, between the 9th and the 12th of March 2023. Professor Suzana Lobo, MD -Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto, São Paulo, Brazil and Investigator of the COVA study in Brazil, will be holding an oralpresentation of the results titled "COVA clinical study:Results from a double-blind, placebo-controlled phase2/3 study to assess efficacy and safety of BIO101 in hospitalized severe COVID-19 patients. Read More

Demo Live Account See Partner Details

Content Topics

Biophytis

Present

Positive

Results

Phase

Cova

Study

2023

Science

Conference

Stock

BPTS

Posted: Mar 9 2023, 02:20

Author Name: Accesswire

BPTS News

By Zacks Investment Research
September 26, 2023

Biophytis (BPTS) Soars 73% on Partnership With Skyepharma

Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).

By Proactive Investors
September 25, 2023

Biophytis shares surge 41% following Covid partnership with France's Skyepharma

Shares of Biophytis (NASDAQ:BPTS, EPA:ALBPS), a clinical-stage biotechnology firm, soared 41% in premarket trading on Nasdaq following the announcemen

By InvestorPlace
September 25, 2023

Why Is Biophytis (BPTS) Stock Up 49% Today?

Biophytis (NASDAQ: BPTS ) stock is rising higher on Monday after the company announced a Sarconeos production agreement. According to a press release

By Accesswire
September 4, 2023

Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 4, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Co

By InvestorPlace
August 8, 2023

Why Is Biophytis (BPTS) Stock Up 18% Today?

Biophytis (NASDAQ: BPTS ) stock is soaring higher on Tuesday as investors react to a positive opinion for its upcoming Phase 3 clinical trial. The big

By MarketBeat
July 18, 2023

Russell 2000 ETF Momentum Sparks Volatility In Small Caps

The iShares Russell 2000 ETF NYSE: IWM has experienced impressive upward momentum in recent weeks. The result of the continued strength in the IWM has

By InvestorPlace
July 18, 2023

Why Is Biophytis (BPTS) Stock Up 66% Today?

Biophytis (NASDAQ: BPTS ) stock is rocketing higher on Tuesday following after announcing a production partnership with SEQENS. According to a press r

By InvestorPlace
March 30, 2023

Why Is Biophytis (BPTS) Stock On The Move Today?

Biophytis (NASDAQ: BPTS ) stock is seeing wild movement on Thursday morning but it's nothing for traders to be worried about. Instead, the company has

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.